Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Recurrence 4Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

romidepsin 8Vincristine 6Cyclophosphamide 6Specimen Handling 5Rituximab 5Biopsy 5fludarabine 4Prednisone 4Methotrexate 4Magnetic Resonance Spectroscopy 4Lactones 4Doxorubicin 4Depsipeptides 4ruxolitinib 3duvelisib 3belinostat 3Nivolumab 3Etoposide 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Bortezomib 3Azacitidine 3tazemetostat 2sodium-iodide symporter 2pegaspargase 2merphos 2liposomal doxorubicin 2cemiplimab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell × Vitamin B 12 × Clear all
NCT00554827 2020-01-03

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
55 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡